SCHEMBL2918664

SCHEMBL2918664

CCO[PH](=O)Oc1cc(C)cc(C)c1-c1c(C(N)=O)[nH]c2ccc(Cl)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2 P11137 14/20 0.53
CYP1A2 P05177 2/20 0.46
HPGD P15428 2/20 0.46
CYP2C19 P33261 2/20 0.46
ALDH1A1 P00352 2/20 0.46
XBP1 P17861 1/20 0.46
CSF1R P07333 1/20 0.42
SIRT1 Q96EB6 1/20 0.39
MEN1 O00255 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2918661 0.88 MAP2 (0.54) MAP2CYP1A2HPGDCYP2C19ALDH1A1
SCHEMBL2535538 0.78 MAP2 (0.52) MAP2CYP1A2HPGDCYP2C19ALDH1A1
SCHEMBL15711419 0.68 MAP2 (0.64) MAP2ALDH1A1SIRT1MEN1KMT2A
SCHEMBL12229839 0.67 MAP2 (0.46) MAP2CYP1A2HPGDCYP2C19ALDH1A1
SCHEMBL12229829 0.67 MAP2 (0.45) MAP2CYP1A2HPGDCYP2C19ALDH1A1
SCHEMBL14036299 0.67 MAP2 (0.45) MAP2CYP1A2HPGDCYP2C19ALDH1A1
SCHEMBL11403058 0.66 MAP2 (1.00) MAP2CYP1A2HPGDCYP2C19ALDH1A1
SCHEMBL2047230 0.66 MAP2 (0.56) MAP2HPGDALDH1A1SIRT1KDM4E
SCHEMBL11557660 0.66 ALDH1A1 (0.74) MAP2CYP1A2HPGDCYP2C19ALDH1A1
SCHEMBL11304644 0.65 ALDH1A1 (0.86) MAP2CYP1A2HPGDCYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2256124-A1 Phospho-indoles as HIV inhibitors IDENIX Pharmaceuticals, Inc. (US) 2010-12-01 EP disclosed
EP-1961757-B1 Phosphoindoles as HIV inhibitors IDENIX PHARMACEUTICALS INC (US) 2010-09-01 EP disclosed
US-7534809-B2 Phospho-indoles as HIV inhibitors IDENIX PHARMACEUTICALS, INC. (US) 2009-05-19 US disclosed
EP-1961757-A1 Phosphoindoles as HIV inhibitors IDENIX Pharmaceuticals, Inc. (US) 2008-08-27 EP disclosed
WO-2006054182-A9 PHOSPHOINDOLES AS HIV INHIBITORS IDENIX CAYMAN LTD 2006-08-17 WO disclosed
US-20060074054-A1 Phospho-indoles as HIV inhibitors IDENIX PHARMACEUTICALS LLC 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074054-A1 Phospho-indoles as HIV inhibitors IDO1, PPP5C, INMT MAP2 320/4885CYP1A2 3279/4885HPGD 3388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.